Physician profile
Erica E Taylor
NPI 1932364551
$1,133.92
in general payments reported to CMS, 2019-2025
11 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $36.55 · 2021: $179 · 2022: $107 · 2023: $229 · 2024: $20.85 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $228.05 | 2022-2023 | Lynparza |
| Mayne Pharma Commercial LLC | $183.66 | 2025 | |
| Agile Therapeutics, INC. | $159.53 | 2021 | |
| Abbvie INC. | $139.89 | 2019-2021 | |
| Hologic Sales and Service, LLC | $118.58 | 2019 | |
| Gilead Sciences, INC. | $107.97 | 2023 | |
| Biogen, INC. | $76.60 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $49.92 | 2019-2020 | |
| Organon LLC | $28.59 | 2025 | Nexplanon |
| Exeltis, USA INC. | $20.85 | 2024 | Slynd |
| Sumitomo Pharma America, INC. | $20.28 | 2025 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.